

DIRECTORS

Executive Directors

Mr. WANG Fucui (王福才), aged 54, is the founder, the chairman of the Board of Directors and the chief executive officer of the Company and is responsible for the overall management, strategic development and major decision-making of the Group. Mr. WANG was appointed as an executive Director of our Company on 30 August 2006. Mr. WANG received a graduation certificate (畢業證) from the Medical Department of Harbin Medical University (哈爾濱醫科大學) in July 1983. Mr. WANG established Ruinian Industry in 1997 to develop his own business and is now the chairman and general manager of Ruinian Industry. He is an associate director of China Food and Drug Administration Magazine (國家食品藥品監督管理局監督雜誌) and a permanent member of the Association of Hong Kong & Kowloon Practitioners of Chinese Medicine Limited. Mr. WANG possesses almost 30 years of experience in the health care and pharmaceutical industry, including over 10 years in the nutritional supplement industry. Mr. WANG served in BeiMan TeGang and its affiliated hospital (北滿特鋼及其附屬醫院), a state-owned entity, from 1983 to 1992 and was appointed as the Medical Superintendent from 1990 to 1992, during which he gained experience in management and administration. From 1992 to 1997, Mr. WANG worked in Shenzhen Hygienic Development Company (深圳市衛生發展公司) as the General Manager and was responsible for the sale of pharmaceutical products. Since the establishment of Ruinian Industry in 1997, Mr. WANG has devoted all his time to the development of the Group. Mr. WANG had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Mr. YU Yan (于岩), aged 45, is an executive Director and is responsible for the Group's production and administration. Mr. YU was appointed as an executive Director of our Company on 30 August 2006. Mr. YU has over 22 years of experience in management. He was the supervisor and factory manager of Northern Steel Development Factory (北鋼北發工業公司) and its subsidiary from 1986 to 1996. Mr. YU joined the Group in December 1997 and is currently the deputy general manager of Ruinian Industry. Mr. YU had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Mr. LI Lin (李林), aged 42, is an executive Director and is responsible for the sales and marketing of the Group. Mr. LI was appointed as an executive Director of our Company on 30 August 2006. Mr. LI is a senior economist recognised by the Department of Personnel of Jiangsu Province based on the assessment by Jiangsu Qualification Evaluation Committee of Senior Professional Positions Specialised in Economic Field (江蘇省經濟專業高級專業技術資格評審委員會). He graduated from Hubei University (湖北大學) in July 1989 and obtained an executive MBA degree from Peking University (北京大學) in January 2007. He was employed by Wuhan Standard Vehicle Parts Factory (武漢汽車標準件廠) as a teacher, administrator of student affairs department and plant manager during the period between 1989 and 1995. He worked for Sanzhu Group Limited (三株集團有限公司) as a manager, regional manager and sales director until 2000 and has over 13 years of experience in sales and marketing. Mr. LI joined the Group in October 2000 and is currently the deputy general manager of Ruinian Industry. Mr. LI had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Mr. YI Lin (伊林), aged 46, is an executive Director and is responsible for the product development and administration of the Group. Mr. YI was appointed as an executive Director of our Company on 30 August 2006. Mr. YI obtained a Bachelor's Degree in Pharmaceutical Preparation (製劑) from Shenyang Medical University (瀋陽藥科大學) in 1987. During the period between 1987 and

DIRECTORS, SENIOR MANAGEMENT AND STAFF

1993, he was employed by Harbin Pharmaceutical Group (哈藥集團股份有限公司) and later promoted to be a sales manager. Mr. YI was the head of sales of Shenzhen Bright Way Pharmaceutical Co., Ltd. (深圳凱程醫藥化工有限公司) during the period between 1993 and 1998 and the provincial, regional and Northern China regional manager of Shenzhen Xinpeng Biological Engineering Ltd. (深圳新鵬生物工程股份有限公司) during the period between 1998 and 2004. He has approximately 20 years of experience in sales and marketing. Mr. YI joined the Group in February 2004 and is currently the deputy general manager of Ruinian Industry. Mr. YI had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Mr. ZHANG Yan (張宴), aged 33, is an executive Director and is responsible for the finance and treasury of the Group. Mr. ZHANG was appointed as an executive Director of our Company on 30 August 2006. Mr. ZHANG completed a diploma study (大學專科) in Finance and Accounting from Shanghai University of Finance & Economics (上海財經大學) in July 1996. He joined Wuxi Desheng Silk Plant (無錫市德生綢廠) in September 1996 and was later promoted as an administrator of the human resources and accounts department. He is not a qualified accountant, but due to his role and responsibility as an administrator of the human resources and accounting departments, he has accumulated over 11 years of experience in accounting. Mr. ZHANG joined the Group in January 2001 and was responsible for the Group's financial and accounting management during the Track Record Period before the appointment of Mr. POON Yick Pang, Philip as the chief financial officer of the Company. He is currently the deputy general manager of Ruinian Industry. Mr. ZHANG had not held any directorship in other listed companies or any major appointments in the three years preceding the Latest Practicable Date.

Ms. AU-YEUNG Kam Ling Celeste (歐陽錦玲), aged 47, is an executive Director and is responsible for the operations of the Group outside the PRC. Ms. AU-YEUNG joined the Group in October 2004 and has been a director of Tongrui since 2007. Ms. AU-YEUNG was appointed as an executive Director of our Company on 28 March 2008. Ms. AU-YEUNG has approximately 17 years of experience in the health food industry. Ms. AU-YEUNG worked in Sunrider International (Hong Kong) Ltd., an international health food company from 1991 to 2001, where she was promoted to District Operation Manager and gained extensive knowledge and experience in the health food markets in Hong Kong and Southeast Asia. Prior to joining the Group, she worked as Operation Manager in both Ta Shing Indomold from 2001 to 2003 and Majestic Group from 2003 to 2004. Ms. AU-YEUNG completed a study in Journalism from Chu Hai College (珠海書院) in Hong Kong in 1986. Chu Hai College was founded in Guangzhou in 1947 and moved with all its teaching resources to Hong Kong and registered under the Education Ordinance, Chapter 279 of the Laws of Hong Kong, with the approval given by the Director of the Education Department to offer post-secondary courses to students in 1949. In early 2003, the Hong Kong Council for Academic Accreditation (HKCAA) confirmed the granting of accreditation status to Chu Hai College. Ms. AU-YEUNG had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

DIRECTORS, SENIOR MANAGEMENT AND STAFF

Non-Executive Director

Mr. IP Tak Chuen, Edmond (葉德銓), aged 57, is a non-executive Director and joined the Group in October 2007. Mr. IP was appointed as a non-executive Director of our Company on 28 March 2008. Mr. IP is and used to be a senior management member at a number of companies. The following chart summarises Mr. IP's positions at such companies:

<u>Company⁽¹⁾</u>	<u>Position</u>
CK Life Sciences ^{(2)*}	senior vice president and chief investment officer
Cheung Kong (Holdings) Limited ^{(3)*}	deputy managing director
Cheung Kong Infrastructure Holdings Limited*	executive director and deputy chairman
TOM Group Limited*	non-executive director
ARA Asset Management Limited*	non-executive director
AVIC International Holding (HK) Limited ^{(4)*}	non-executive director
Excel Technology International Holdings Limited*	non-executive director
The Ming An (Holdings) Company Limited ^{(5)*}	non-executive director
Shougang Concord International Enterprises Company Limited*	non-executive director
ARA Asset Management (Singapore) Limited, the manager of Fortune Real Estate Investment Trust*	director
ARA Trust Management (Suntec) Limited, the manager of Suntec Real Estate Investment Trust*	director
Critical Path, Inc. ^{(6)*}	director
CrossCity Motorway Pty Ltd ^{(7)♦}	director
CrossCity Motorway Nominees No. 1 Pty Ltd ^{(7)♦}	director
CrossCity Motorway Nominees No. 2 Pty Ltd ^{(7)♦}	director
CrossCity Motorway Holdings Pty Ltd ^{(7)♦}	director
CrossCity Motorway Finance Pty Ltd ^{(7)♦}	director

Notes:

- (1) All marked with a * are listed companies or REITs listed in Singapore except for The Ming An (Holdings) Company Limited, which was delisted on 2 November 2009, and Critical Path, Inc., whose shares were formerly listed on the Nasdaq National Market in the United States. All companies marked with a ♦ were insolvent and incorporated in Australia, and a voluntary administrator and a receiver and manager were appointed on 27 December 2006. Mr. IP was a director in such companies (collectively the "CrossCity companies") before 22 December 2006. During their existence, the principal business of the CrossCity companies was the design, construction and operation of the Cross City Tunnel in Sydney, Australia, which was acquired by ABN AMRO and Leighton Contractors consortium after the insolvency of the CrossCity companies.
- (2) CK Life Sciences is a company listed on the Main Board of the Stock Exchange. Mr. IP joined the CK Life Sciences Group in December 1999.
- (3) Mr. IP joined the Cheung Kong Group in 1993.
- (4) The company was formerly known as CATIC International Holdings Limited.
- (5) Mr. IP resigned from the company on 27 November 2009.
- (6) Mr. IP resigned from the company on 31 July 2007.
- (7) Mr. IP resigned from the companies on 22 December 2006.

Mr. IP obtained a Bachelor of Arts degree in Economics in 1975 and a Master of Science degree in Business Administration in 1977. Save as aforesaid, Mr. IP had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Independent Non-Executive Directors

Mr. WONG Lung Tak Patrick, J.P. (黃龍德), aged 61, is an independent non-executive Director and joined the Group in March 2008. Mr. WONG was appointed as an independent non-executive Director of our Company on 28 March 2008. Mr. WONG is a fellow member of the Hong Kong Institute of Certified Public Accountants, the Institute of Chartered Accountants in England and Wales, the Association of Certified Accountants, the Association of International Accountants, the Society of Chinese Accountants and Auditors of Hong Kong, the Institute of Chartered Secretaries and Administrators, the Hong Kong Institute of Company Secretaries, the Taxation Institute of Hong Kong and the Hong Kong Institute of Directors Ltd. Mr. WONG is the managing director of Wong Lam Leung & Kwok CPA Limited. He has over 30 years' experience in the accountancy profession. Among his qualifications, he was awarded a Badge of Honour in 1993 by the Queen of England and was appointed as a Justice of Peace in 1998. Mr. WONG is involved in many other community services, holding posts in various organisations and committees in government and voluntary agencies. Mr. WONG has not, by himself or through the firm he practices with, provided professional services to the Group in the past. As of the Latest Practicable Date, Mr. WONG had been an independent non-executive director of Galaxy Entertainment Group Limited, CC Land Holdings Limited, Water Oasis Group and China Precious Metal Resources Holdings Co., Ltd., all of which are companies whose shares are listed on the Main Board of the Stock Exchange and an independent non-executive director of Vertex Group Limited, a company whose shares are listed on the Growth Enterprise Market Board of the Stock Exchange. Save as aforesaid, he had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Dr. FONG Chi Wah (方志華), aged 47, is an independent non-executive Director and joined the Group in March 2008. Dr. FONG was appointed as an independent non-executive Director of our Company on 28 March 2008. Dr. FONG is a Chartered Financial Analyst, a member of Hong Kong Institute of CPAs and the Institute of Certified Management Accountants, Australia, and the Hong Kong Institute of Directors. Dr. FONG has over 20 years of experience in various sectors of the financial industry, including direct investment, project and structured finance and capital markets, with a focus on the PRC and Hong Kong. Dr. FONG was a director of Baring Capital (China) Management Limited and held various management positions in ING Bank. He was appointed as an independent non-executive director of Syscan Technology Holdings Limited on 19 December 2003 and as an executive director of National Investments Fund Limited on 1 November 2005, and both companies are listed on the Stock Exchange. Dr. FONG obtained a bachelor's degree in management science (economics) from Lancaster University, United Kingdom, in 1984, a master's degree in business administration from Warwick University, United Kingdom, in 1986, a master's degree in investment management from the Hong Kong University of Science and Technology in 1999, a master's degree in practising accounting from Monash University, Australia, in 2001 and a doctorate in business administration from the Hong Kong Polytechnic University in 2007. Dr. FONG has not, by himself or through the firm in which he practices, provided professional services to the Group in the past. Save as aforesaid, he had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Mr. Bernard Ban-yew YAW (饒萬有), aged 49, is an independent non-executive Director and joined the Group in November 2009. Mr. YAW was appointed as an independent non-executive Director of our Company on 2 November 2009. Mr. YAW has over 20 years of experience in management and investment. He has joined Dubai Ventures Group Sdn Bhd ("DVG") as Senior Vice

President in charge of Private Equity since 1 December 2005. Dubai Ventures Group is a wholly owned subsidiary of Dubai Group, whose sole shareholder is HH Sheikh Mohammed bin Rashid Al-Maktoum, the ruler of Dubai and the Prime Minister of the United Arab Emirates. DVG is the regional office for Dubai Investment Group in Kuala Lumpur and its primary investment focus is equity investment in this region including Malaysia, Singapore, Thailand, Indonesia, Vietnam, Philippines, Australasia and North Asia including China. DVG has regional offices in Kuala Lumpur, Hong Kong, London, and New York with its headquarters in Dubai, United Arab Emirates. Prior to joining DVG, Mr. YAW was with Malaysia Venture Capital Management Berhad (“MAVCAP”), a wholly owned subsidiary of the Ministry of Finance Inc., Malaysia, which is the investment arm of the Malaysian government, in various capacities. He was the Senior Vice President of Direct Ventures, in charge of Seed Ventures and Agency Ventures and was in charge of the strategic implementation of the Cradle Investment Programme since MAVCAP’s inception in April 2001. Prior to joining MAVCAP, he was the President and CEO of Intelliquis Inc., a NASDAQ listed company in which he was in charge of raising early and later stage capital, strategic corporate and worldwide expansion and ultimately engineering the listing exercise in NASDAQ. Mr. YAW graduated from Oral Roberts University in 1985 with a bachelor of science degree in computer science. Mr. YAW had not held any directorship in other listed public companies or any major appointments in the three years preceding the Latest Practicable Date.

Non-executive Directors’ Interests In Competing Businesses

Our non-executive Director, namely Mr. IP Tak Chuen, Edmond, is an executive director of CK Life Sciences and holds approximately 0.02% of equity interests in CK Life Sciences.

CK Life Sciences is a company whose shares are listed on the Main Board of the Stock Exchange. It is engaged in the business of research and development, manufacturing, commercialisation, marketing and selling of environmental and human health products, as well as investment in various financial and investment products, and such business may be made through subsidiaries, associated companies or by way of other forms of investments. According to its 2009 interim report, for the six months ended 30 June 2009, profit after tax and total net assets of CK Life Sciences were approximately HK\$257 million and approximately HK\$4.86 billion respectively.

Mr. IP is considered as having interests in a business which competes or is likely to compete with the Group’s business under Rule 8.10(2) of the Listing Rules.

The daily business of our Group is managed by our executive Directors and senior management of our Group, and our business, finance and operations are separate from and independent of Mr. IP and CK Life Sciences. Furthermore, our Group has also appointed three independent non-executive Directors to ensure that the interests of all Shareholders will be adequately represented. In this circumstance, our Group is capable of carrying on its businesses independently of such competing business.

After Listing, the Directors will continue to prominently disclose details as required under Rule 8.10(2)(a) of the Listing Rules of any of their interests in a business which competes or is likely to compete, either directly or indirectly, with our Group’s business in our annual reports or any change in details previously disclosed in this prospectus and our annual reports.

SENIOR MANAGEMENT

Mr. POON Yick Pang, Philip, aged 40, is our Chief Financial Officer and Company Secretary. He joined the Company in June 2008. Mr. POON has over 15 years of corporate finance and accounting experience. Prior to joining the Company, he was the Director of Finance of China Medical Technologies, Inc., a NASDAQ listed company engaged in the manufacture and sales of advanced medical devices in the PRC from 2007 to 2008, and the Senior Vice President, Qualified Accountant and Company Secretary of Paradise Entertainment Limited, a company listed on the Stock Exchange, from 2002 to 2007. Mr. POON also served various positions in Advent International Corporation, a global private equity firm, and in major listed companies in Hong Kong, including Lenovo Group Limited and Sun Hung Kai Properties Limited. Mr. POON obtained a Bachelor of Commerce degree from the University of New South Wales in 1993 and is a holder of a Chartered Financial Analyst charter of the CFA Institute, a Certified Practising Accountant (Australia) and a fellow of the Hong Kong Institute of Certified Public Accountants.

Mr. QUAN Guangde (全廣德), aged 60, is the manager of our Production Department and an assistant to our chief executive officer. Mr. QUAN is responsible for supervising the production of our nutritional health products. He joined our Group in October 2004 and was a mechanical engineer and head of the engineering team of our Production Department before being promoted to his current positions. Mr. QUAN has over 28 years of experience in mechanical engineering, and was qualified as an engineer in 1987 and a senior engineer in 1996 in the PRC. Prior to joining our Group, Mr. QUAN worked for various companies in the PRC as a mechanical engineer.

Mr. YUAN Jianjun (袁建軍), aged 39, is the manager of our Sales Auditing Department and an assistant to our chief executive officer. Mr. YUAN is responsible for the auditing and analysis of the sales business and marketing and the daily management of the Group. He graduated from the Jiangxi School of Finance & Economics in July 1994, majoring in Financial Accounting. He joined our Group in August 2006 and has over 14 years of experience in financial accounting and auditing. He was qualified as an Accountant in 2004 in the PRC. Prior to joining our Group, Mr. YUAN served in various companies in the PRC specialising in accounting and auditing.

AUDIT COMMITTEE

We established an audit committee on 1 February 2010 with written terms of reference as suggested under the Code on Corporate Governance Practices as set out in Appendix 14 to the Listing Rules.

The primary duties of the audit committee are to review and supervise our financial reporting processes and internal control system.

The audit committee has three members comprising Mr. WONG Lung Tak Patrick, J.P., Dr. FONG Chi Wah and Mr. Bernard Ban-yew YAW, all of whom are independent non-executive Directors. The chairman of the audit committee is Mr. WONG Lung Tak Patrick, J.P.

REMUNERATION COMMITTEE

We established a remuneration committee on 1 February 2010 with terms of reference in compliance with the Code on Corporate Governance Practices set out in Appendix 14 of the Listing Rules.

DIRECTORS, SENIOR MANAGEMENT AND STAFF

The primary responsibilities of the remuneration committee are to make recommendations to the Board on the remuneration package of the Directors and senior management personnel and to ensure that no Director or any of his/her associates is involved in deciding his/her own remuneration.

The remuneration committee has four members comprising Mr. WANG Fucai, Mr. WONG Lung Tak Patrick, J.P., Dr. FONG Chi Wah and Mr. Bernard Ban-yew YAW, a majority of whom are independent non-executive Directors. The chairman of the remuneration committee is Dr. FONG Chi Wah.

COMPANY SECRETARY

Mr. POON Yick Pang, Philip serves as the secretary of our Company. For details of Mr. POON's background, please refer to the section headed "— Senior Management."

COMPLIANCE ADVISER

We have appointed Sinopac Securities (Asia) Limited as our compliance adviser pursuant to Rule 3A.19 of the Listing Rules. The material terms of the compliance adviser's agreement between us and Sinopac Securities (Asia) Limited include the following:

- (a) Sinopac Securities (Asia) Limited has been appointed as our compliance adviser for the purpose of Rule 3A.19 of the Listing Rules for a period commencing on the Listing Date and ending on the date on which we comply with Rule 13.46 of the Listing Rules in respect of our financial results for the first full financial year commencing after the Listing Date; and
- (b) pursuant to Rule 3A.23 of the Listing Rules, Sinopac Securities (Asia) Limited will advise us in the following circumstances:
 - (i) before the publication of any regulatory announcement, circular or financial report;
 - (ii) where a transaction, which might be a notifiable or connected transaction (as defined under the Listing Rules), is contemplated including share issues and share repurchases;
 - (iii) where we propose to use the proceeds of the Global Offering in a manner different from that detailed in this prospectus or where our business activities, developments or results deviate from any information in this prospectus; and
 - (iv) where the Stock Exchange makes an inquiry with us regarding unusual movements in the price or trading volume of the Shares.

STAFF

All our employees are employed under employment contracts which set out fully, among other things, the employee's responsibilities, remuneration and grounds for termination of employment. The Group has maintained good working relationships with our employees and does not foresee any difficulties in the recruitment and retention of experienced staff. During the Track Record Period, there has not been any interruption to our operations as a result of labour disputes.

DIRECTORS, SENIOR MANAGEMENT AND STAFF

The remuneration package of our staff includes salary, bonus and cash subsidies. Generally, the employee salaries are determined based on the employees' qualifications, experience, position and seniority. We assess our employee remuneration on an annual basis, in order to determine whether any bonus or salary adjustments are required to be made. Overall, we believe that our remuneration package is competitive in comparison with others offered in the market.

Under the existing arrangement, the aggregate amount of remuneration payable to the Directors for the year ending 31 December 2010 is expected to be approximately RMB5.8 million.

Our Group has complied with all the relevant laws, regulations and requirements in relation to fair labour standards and employment contracts of its employees in the PRC and Hong Kong.

BENEFIT SCHEMES

The Group participates in a state-organised pension and staff welfare schemes operated by the PRC government for its full-time employees in the PRC, pursuant to which we are required to make monthly contributions of 30.4% of the employee's monthly salary to these plans. For each of the periods within the Track Record Period, the Group's contribution to these benefit schemes amounted to approximately RMB0.3 million, RMB0.5 million, RMB1.9 million and RMB1.0 million, respectively.

PRE-IPO SHARE OPTION SCHEME

In order to recognise the contributions of certain employees and individuals to our Group and to continue to retain and attract key employees, our Company, together with Strong Ally Limited, Furui's wholly-owned subsidiary incorporated in the BVI, adopted the Pre-IPO Share Option Scheme. The Pre-IPO Share Option Scheme consists of two parts, namely options to purchase from Strong Ally Limited up to an aggregate of 20,000,000 Shares and options to subscribe for an aggregate of 20,000,000 Shares from our Company. The total number of the underlying Shares which are the subject of the options granted under the Pre-IPO Share Option Scheme will not exceed 40,000,000 Shares, representing 4% of our issued share capital as of the Listing Date (assuming that the Over-allotment Option is not exercised and the options granted under the Pre-IPO Share Option Scheme are not exercised), or approximately 3.92% of our issued share capital (assuming the Over-allotment Option is not exercised) as enlarged by the issue of additional Shares upon exercise of all options granted under the second part of the Pre-IPO Share Option Scheme.

The terms of the Pre-IPO Share Option Scheme are substantially the same as the Share Option Scheme except for the following conditions:

- (a) the exercise price per Share under the Pre-IPO Share Option Scheme shall be the Offer Price;
- (b) the grantees shall not, within six months from the Listing Date, exercise any of the options granted under the Pre-IPO Share Option Scheme;
- (c) the Pre-IPO Share Option Scheme will only become effective if the following conditions precedent are fulfilled:
 - (i) the Listing Committee of the Stock Exchange granting approval on the listing of, and permission to deal in, any Shares to be issued upon the exercise of options granted under the Pre-IPO Share Option Scheme;

DIRECTORS, SENIOR MANAGEMENT AND STAFF

- (ii) the Global Offering becoming unconditional (including, if relevant, as a result of the waiver of any condition(s)) and not being terminated in accordance with the terms thereof; and
- (iii) the commencement of dealing in the Shares on the Stock Exchange;
- (d) option granted under the Pre-IPO Share Option Scheme shall lapse if the conditions precedent are not fulfilled; and
- (e) the maximum number of Shares granted under the Pre-IPO Share Option Scheme shall not exceed 40,000,000 Shares in total.

As of the Latest Practicable Date, options to purchase or subscribe for an aggregate of 40,000,000 Shares at the Offer Price had been granted to 104 grantees under the Pre-IPO Share Option Scheme, which are subject to the conditions listed above and for a consideration of HK\$1.00 from each grantee. The options granted under the Pre-IPO Share Option Scheme are valid for three years following the Listing Date. One-third of the options granted may be exercised between the expiry date of six months after the Listing Date and the expiry date of three years after the Listing Date; and 1/36 of the options granted will become exercisable at the end of each calendar month beginning 12 months after the Listing Date until the expiry date of three years after the Listing Date in 24 tranches. No options will be granted under the Pre-IPO Share Option Scheme on or after the Listing Date.

Assuming that all options granted by us under the Pre-IPO Share Option Scheme were exercised in full on the Listing Date (but assuming the Over-allotment Option is not exercised), the shareholding interest of the public in our issued share capital as of the Listing Date would be decreased from approximately 58.12% to approximately 56.98%. Assuming we have had the number of Shares expected to be in issue following the Global Offering (assuming the Over-allotment Option is not exercised), namely 1,000,000,000 Shares, as of 30 September 2009, our earnings per Share for the nine months ended 30 September 2009 would have been reduced from RMB17.6 cents to RMB13.2 cents, and then further down to RMB13.0 cents if all options granted under the Pre-IPO Share Option Scheme are also assumed to have been exercised in full as of 30 September 2009. For details of the options that have been granted to Directors and other grantees under the Pre-IPO Share Option Scheme, please see the section headed “Statutory and General Information — Other Information — Pre-IPO Share Option Scheme” in Appendix VIII to this prospectus.

Save as disclosed above and in Appendix VIII to this prospectus, no option or similar rights had been granted or agreed to be granted by our Company or Strong Ally Limited under the Pre-IPO Share Option Scheme as of the Latest Practicable Date.

SHARE OPTION SCHEME

The Company has conditionally adopted the Share Option Scheme whereby certain selected classes of participants (including without limitation the executive and independent non-executive Directors and staff of members of the Group) may be granted options to acquire Shares. The principal terms of the Share Option Scheme are summarised in the section headed “Other Information — Share Option Scheme” in Appendix VIII to this prospectus.